论文部分内容阅读
围绕单抗技术,有很多技术细节或新的亮点值得挖掘。单克隆抗体类治疗性药物简称单抗药物,号称是“生物导弹”。2010年全球单抗药物销售额超过480亿美元。2009年美国FDA共批准了25种新药上市,在其中的6种生物药品中,有4种是人源单抗,2010年FDA又批准2种人源单抗,可见单抗将成为生物公司研发的焦点。
Around the monoclonal antibody technology, there are many technical details or new highlights worth digging. Monoclonal antibody therapeutic drug referred to as monoclonal antibody, known as “biological missile ”. In 2010 the global sales of monoclonal antibody drugs more than 48 billion US dollars. In 2009, the FDA approved a total of 25 new drugs. Of the 6 biopharmaceutical products, 4 are human monoclonal antibodies. In 2010, the FDA approved 2 human monoclonal antibodies. The result shows that the monoclonal antibody will become a bio-research and development company Focus.